Skip to main content

Fiscal Wizard · Single-issue tearsheet

MRK / Aug 13, 2026 Run #13880

MRK

Merck & Company, Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Composite verdict

A 75.8 / 100
Bullish setup · Reversal 7 drivers · 3 gates blocking
  • Elder Force Index
  • Multi Top/Bottom
  • Vortex Signal
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 1st of 9 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 17 signals0% Bear
Momentum Bullish 94Mean-reversion Neutral 53

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -76%
Asset value $21.32Earnings power value $73.26Price $134.69

Priced above its no-growth earnings power value ($73.26/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

51.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Payout Ratio 87
Margin of Safety 0
OCF to Net Income 80
Cash Conversion Cycle 0
Return on Invested Capital 77
Inventory Turnover 0

Technicals Bullish

99.7 / 100

Bullish setup leads (Elder Force Index, Multi Top/Bottom, Vortex Signal); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Elder Force Index 93
Multi Top/Bottom 88
Vortex Signal 85

Risk Gates

3 blocking 6 caution

3 guards active, 26 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MRK.